Cystic Fibrosis
Conditions
Keywords
Exercise
Brief summary
Physical activity and exercise have become an accepted and valued component of cystic fibrosis care. Regular physical activity and exercise can slow the rate of decline of pulmonary function, improve physical fitness, and enhance quality of life. However, motivating people to be more active is challenging. Supervised, facility-based exercise programs are expensive and labor intensive (since groups of patients with CF cannot exercise together in the same physical location). Home-based exercise using an interactive exergame device may be an effective way to improve adherence to an exercise program for patients with CF. Therefore, the primary objective of this study is to evaluate the effects of a 12-week, home-based exergame exercise intervention on aerobic capacity (peak VO2). The secondary endpoint is nasal potential difference, an indicator of how well sodium and chloride flow across the mucous membranes in the nose. Other outcomes include patient-reported quality of life and habitual physical activity level. Following baseline assessments participants will be begin a 12 week, partially-supervised exercise program consisting of at least 90 minutes per week of aerobic and resistance exercise training using the Nintendo Wii Fit Plus exergaming device. Participants will receive at least monthly follow-up phone calls to provide additional exercise counseling and motivation. After 12 weeks, they will continue with the exergame intervention for another 12 weeks, but without external supervision.
Interventions
BEHAVIORALExercise
Aerobic and strength training using the Wii Fit for ≥ 30 min, ≥3 days/week, for 12 weeks, at a moderate intensity (Borg CR10 3-5).
Sponsors
University of Alabama at Birmingham
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* confirmed diagnosis of CF * currently sedentary (\<60 min/week of physical activity) * stable clinical condition (no exacerbation in last 6 weeks)
Exclusion criteria
* nasal surgery for polyposis in the past 2 years * participating or have participated (in the past 30 days) in another clinical trial which can affect the outcomes of the proposed study * unable to read/speak English * recurrent pneumothorax (in the past 6 months) * hemoptysis (hospitalized in the past 6 months) * uncontrolled CF-related diabetes (HbA1c \> 10%)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Peak oxygen consumption (VO2 peak) | 12 and 24 weeks | Measure of aerobic physical fitness |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Nasal potential difference (NPD) | 12 weeks | Measure of respiratory/airway ion transport |
| Cystic Fibrosis Questionnaire-Revised (CFQ-R)) | 12 and 24 weeks | Health-related quality of life questionnaire (especially respiratory-related symptoms) |
| Habitual physical activity level | 12 and 24 weeks | Accelerometer-based measure of frequency, intensity and duration of bouts of physical activity while user is wearing device. |
Countries
United States
Outcome results
None listed